Larry Ellison Donates $200 Million for Cancer Research

The Oracle cofounder’s gift will fund a new institute at the University of Southern California.

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Larry EllisonFLICKR, ORACLE PRLarry Ellison, the billionaire cofounder of software giant Oracle, has donated $200 million to the University of Southern California (USC) to fund the creation of a new institute for cancer research, the university announced yesterday (May 11). The Lawrence J. Ellison Institute for Transformative Medicine will be led by USC Professor of Medicine and Engineering David Agus, and will combine diverse fields of research.

“This investment by Larry Ellison in USC is as inspirational as it is momentous, and it will serve as a dynamic force for change in how we approach cancer treatment and prevention,” USC President C. L. Max Nikias said in the statement.

The money will mostly be used to fund a new building in west Los Angeles—set to open in around 2.5 years—and to support research and artist residency programs, Agus told Bloomberg Technology. “There will be clinics, engineering labs, think tanks, and kids will be able to go on tours all day because we need to excite the next generation,” he said.

Ellison, who is worth nearly $50 billion, has previously given money to aging research, animal welfare, and polio eradication efforts, The Wall ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies